Drug Trial Radar · NCT02752074
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Last checked: Nov 19, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
706
Actual
Start
Jun 21, 2016
Primary completion
Jan 8, 2018
Study completion Aug 16, 2019
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Apr 26, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in participants with unresectable or metastatic melanoma
Conditions
- Melanoma
Interventions
pembrolizumab + epacadostatDrug
* Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1) * Epacadostat will be administered orally daily starting at Day 1 (Week 1)
pembrolizumab + placeboDrug
* Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1) * Placebo will be administered orally daily starting at Day 1 (Week 1)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free SurvivalTime frame: Assessed every 9 weeks for duration of study participation which is estimated to be 24 months
- Overall Survival (OS) Rate at 6 MonthsTime frame: Assessed every 9 weeks of study participation which is estimated to be 24 months. The OS rate at Month 6 was calculated.
Locations
129 sites in 23 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Scottsdale, Arizona
Site not named
Little Rock, Arkansas
Site not named
Los Angeles, California
Site not named
San Francisco, California
Site not named
Santa Barbara, California
Site not named
Santa Monica, California
Site not named
Aurora, Colorado
Site not named
Denver, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Fort Lauderdale, Florida
Site not named
Jacksonville, Florida
Site not named
Ocala, Florida
Site not named
West Palm Beach, Florida
Site not named
Chicago, Illinois
Site not named
Peoria, Illinois
Site not named
Iowa City, Iowa
Site not named
Kansas City, Kansas
Site not named
Lutherville, Maryland
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Fridley, Minnesota
Site not named
Billings, Montana
Site not named
Omaha, Nebraska
Site not named
Las Vegas, Nevada
Site not named
Rochester, New York
Site not named
Charlotte, North Carolina
Site not named
Philadelphia, Pennsylvania
Site not named
Nashville, Tennessee
Site not named
Austin, Texas
Site not named
Dallas, Texas
Site not named
Salt Lake City, Utah
Site not named
Fairfax, Virginia
Site not named
Spokane, Washington
Site not named
Camperdown, New South Wales, Australia
Site not named
Westmead, New South Wales, Australia
Site not named
Wollstonecraft, New South Wales, Australia
Site not named
Cairns, Queensland, Australia
Site not named
Greenslopes, Queensland, Australia
Site not named
Kurralta Park, South Australia, Australia
Showing 40 of 129 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.